Literature DB >> 35882698

Investigating the stabilisation of IFN-α2a by replica exchange molecular dynamics simulation.

Daixi Li1, Peiqin Chen2, Qingli Dong2, Baolin Liu2, Wujie Zhang3, Dong-Qing Wei4,5, Baisong Guo6.   

Abstract

Current biopharmaceutical drugs are mainly a class of peptides or proteins that play an essential role in the treatment of many diseases. Such peptides/proteins are usually thermally unstable and may lose their bioactivity when exposed to ambient conditions. Therefore, they are not suitable for long-term storage. Lyophilisation is the most common method to prolong shelf life of solid peptide/protein drugs; however, the freeze-drying process can lead to irreversible damage. In the present study, human interferon-alpha 2a (IFN-α2a) was selected as a model protein drug; four disaccharides (β-lactose, β-maltose, sucrose, and trehalose) were selected as bioactive protectants. We investigated the effects of different protectants on IFN-α2a under various ambient conditions (vacuum, dry state, and aqueous solution) using replica exchange molecular dynamics simulation. The protective effect of β-maltose on IFN-α2a was the highest in aqueous solution and dry state, β-lactose showed a poor protective effect in all three conditions, the performance of sucrose was good in all conditions, and trehalose showed a better protective effect under vacuum conditions and in aqueous solution. Disaccharides form H-bonds with water, thereby preventing water from the tertiary structure of proteins. Trehalose forms strong H-bonds with water which explains its extraordinary stability.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bioactive protectant; Disaccharides; IFNα2a; Molecular dynamics simulation

Mesh:

Substances:

Year:  2022        PMID: 35882698     DOI: 10.1007/s00894-022-05212-w

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   2.172


  43 in total

Review 1.  Forced degradation of therapeutic proteins.

Authors:  Andrea Hawe; Michael Wiggenhorn; Marco van de Weert; Joerg H O Garbe; Hanns-Christian Mahler; Wim Jiskoot
Journal:  J Pharm Sci       Date:  2011-11-14       Impact factor: 3.534

2.  Drug discovery: past, present and future.

Authors:  Nafees N Malik
Journal:  Drug Discov Today       Date:  2008-11       Impact factor: 7.851

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 4.  Protein aggregation--pathways and influencing factors.

Authors:  Wei Wang; Sandeep Nema; Dirk Teagarden
Journal:  Int J Pharm       Date:  2010-02-24       Impact factor: 5.875

Review 5.  Administration strategies for proteins and peptides.

Authors:  D Ibraheem; A Elaissari; H Fessi
Journal:  Int J Pharm       Date:  2014-10-30       Impact factor: 5.875

6.  A review on parenteral delivery of peptides and proteins.

Authors:  Divisha Jain; S Shahe Mahammad; Pirthi Pal Singh; Ravinder Kodipyaka
Journal:  Drug Dev Ind Pharm       Date:  2019-06-28       Impact factor: 3.225

Review 7.  Parenteral protein formulations: An overview of approved products within the European Union.

Authors:  V Gervasi; R Dall Agnol; S Cullen; T McCoy; S Vucen; A Crean
Journal:  Eur J Pharm Biopharm       Date:  2018-07-11       Impact factor: 5.571

8.  Alternative routes of administration for systemic delivery of protein pharmaceuticals.

Authors:  Eva Horn Moeller; Lene Jorgensen
Journal:  Drug Discov Today Technol       Date:  2008

9.  Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients.

Authors:  Sahar A Elsayed; Mohamed A Esmail; Randa M Ali; Omar M Mohafez
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

10.  Production of a novel multi-epitope peptide vaccine for cancer immunotherapy in TC-1 tumor-bearing mice.

Authors:  Navid Nezafat; Mohammad Sadraeian; Mohammad Reza Rahbar; Mohammad Javad Khoshnoud; Milad Mohkam; Ahmad Gholami; Mehrzad Banihashemi; Younes Ghasemi
Journal:  Biologicals       Date:  2014-11-29       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.